|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mosesson MW: Fibrinogen and fibrin
structure and functions. J Thromb Haemost. 3:1894–1904. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma XK, Wen JY, Chen ZH, Lin Q, Li X, Dong
M, Wei L, Chen J, Wang TT, Ruan DY, et al: Clinical significance of
plasma fibrinogen level in patients with prostate cancer. J Clin
Oncol. 31:2013.
|
|
6
|
Son HJ, Park JW, Chang HJ, Kim DY, Kim BC,
Kim SY, Park SC, Choi HS and Oh JH: Preoperative plasma
hyperfibrinogenemia is predictive of poor prognosis in patients
with nonmetastatic colon cancer. Ann Surg Oncol. 20:2908–2913.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsuda S, Takeuchi H, Kawakubo H, Fukuda
K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T and Kitagawa
Y: Cumulative prognostic scores based on plasma fibrinogen and
serum albumin levels in esophageal cancer patients treated with
transthoracic esophagectomy: Comparison with the Glasgow prognostic
score. Ann Surg Oncol. 22:302–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verheul HM, Hammers H, van Erp K, Wei Y,
Sanni T, Salumbides B, Qian DZ, Yancopoulos GD and Pili R: Vascular
endothelial growth factor trap blocks tumor growth, metastasis
formation, and vascular leakage in an orthotopic murine renal cell
cancer model. Clin Cancer Res. 13:4201–4208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamashita H, Kitayama J and Nagawa H:
Hyperfibrinogenemia is a useful predictor for lymphatic metastasis
in human gastric cancer. Jpn J Clin Oncol. 35:595–600. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: Clinical and
prognostic significance of preoperative plasma hyperfibrinogenemia
in gallbladder cancer patients following surgical resection: A
retrospective and in vitro study. BMC cancer. 14:5662014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones JM, McGonigle NC, McAnespie M, Cran
GW and Graham AN: Plasma fibrinogen and serum C-reactive protein
are associated with non-small cell lung cancer. Lung Cancer.
53:97–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene F and Trotti A: AJCC cancer staging manual. 7th. New York,
NY: Springer; 2010
|
|
13
|
Gatt A, Bonello F, Buttigieg R, Debono S,
Brincat P, Grima C, Gatt P, Lofaro T and Laspina S: Flow cytometry
and thromboelastography to assess platelet counts and coagulation
in patients with haematological malignancies. Blood Transfus.
12:479–484. 2014.PubMed/NCBI
|
|
14
|
Kurup A, Lin C, Murry DJ, Dobrolecki L,
Estes D, Yiannoutsos CT, Mariano L, Sidor C, Hickey R and Hanna N:
Recombinant human angiostatin (rhAngiostatin) in combination with
paclitaxel and carboplatin in patients with advanced non-small-cell
lung cancer: A phase II study from Indiana University. Ann Oncol.
17:97–103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altiay G, Ciftci A, Demir M, Kocak Z, Sut
N, Tabakoglu E, Hatipoglu ON and Caglar T: High plasma D-dimer
level is associated with decreased survival in patients with lung
cancer. Clin Oncol (R Coll Radiol). 19:494–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuderer NM, Khorana AA, Lyman GH and
Francis CW: A meta-analysis and systematic review of the efficacy
and safety of anticoagulants as cancer treatment: Impact on
survival and bleeding complications. Cancer. 110:1149–1161. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
dos Santos Silva I, De Stavola BL, Pizzi C
and Meade TW: Circulating levels of coagulation and inflammation
markers and cancer risks: Individual participant analysis of data
from three long-term cohorts. Int J Epidemiol. 39:699–709. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Palumbo JS, Talmage KE, Massari JV, La
Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M and Degen JL:
Platelets and fibrin(ogen) increase metastatic potential by
impeding natural killer cell-mediated elimination of tumor cells.
Blood. 105:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palumbo JS, Potter JM, Kaplan LS, Talmage
K, Jackson DG and Degen JL: Spontaneous hematogenous and lymphatic
metastasis, but not primary tumor growth or angiogenesis, is
diminished in fibrinogen-deficient mice. Cancer Res. 62:6966–6972.
2002.PubMed/NCBI
|
|
20
|
Fahham D, Merquiol E, Gilon T, Marx G and
Blum G: Insoluble fibrinogen particles for harvesting and expanding
attachment-dependent cells and for trapping suspended cancer cells
in the presence of blood. Biomed Mater. 10:0250102015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palumbo JS, Kombrinck KW, Drew AF, Grimes
TS, Kiser JH, Degen JL and Bugge TH: Fibrinogen is an important
determinant of the metastatic potential of circulating tumor cells.
Blood. 96:3302–3309. 2000.PubMed/NCBI
|
|
22
|
Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung
JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, et al: Liver
metastasis predicts poorer prognosis in stage IV lung
adenocarcinoma patients receiving first-line gefitinib. Lung
Cancer. 88:187–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang
JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus
chemotherapy versus placebo plus chemotherapy in
EGFR-mutation-positive non-small-cell lung cancer after progression
on first-line gefitinib (IMPRESS): A phase 3 randomised trial.
Lancet Oncol. 16:990–998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakamichi S, Kubota K, Horinouchi H, Kanda
S, Fujiwara Y, Nokihara H, Yamamoto N and Tamura T: Successful
EGFR-TKI rechallenge of leptomeningeal carcinomatosis after
gefitinib-induced interstitial lung disease. Jpn J Clin Oncol.
43:422–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishiguro Y, Ishiguro H and Miyamoto H:
Epidermal growth factor receptor tyrosine kinase inhibition
up-regulates interleukin-6 in cancer cells and induces subsequent
development of interstitial pneumonia. Oncotarget. 4:550–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamaguchi T, Yamamoto Y, Yokota S,
Nakagawa M, Ito M and Ogura T: Involvement of interleukin-6 in the
elevation of plasma fibrinogen levels in lung cancer patients. Jpn
J Clin Oncol. 28:740–744. 1998. View Article : Google Scholar : PubMed/NCBI
|
